MA71468A - Compositions et méthodes pour diminuer l'expression de tau - Google Patents

Compositions et méthodes pour diminuer l'expression de tau

Info

Publication number
MA71468A
MA71468A MA71468A MA71468A MA71468A MA 71468 A MA71468 A MA 71468A MA 71468 A MA71468 A MA 71468A MA 71468 A MA71468 A MA 71468A MA 71468 A MA71468 A MA 71468A
Authority
MA
Morocco
Prior art keywords
compositions
methods
tau expression
decreasing tau
decreasing
Prior art date
Application number
MA71468A
Other languages
English (en)
Inventor
Manuela Polydoro Ofengeim
Jan Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA71468A publication Critical patent/MA71468A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA71468A 2015-12-21 2016-12-19 Compositions et méthodes pour diminuer l'expression de tau MA71468A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562270165P 2015-12-21 2015-12-21
EP24154346.1A EP4406541A3 (fr) 2015-12-21 2016-12-19 Compositions et méthodes pour diminuer l'expression de tau

Publications (1)

Publication Number Publication Date
MA71468A true MA71468A (fr) 2025-04-30

Family

ID=57758674

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44426A MA44426B1 (fr) 2015-12-21 2016-12-19 Compositions et méthodes pour diminier l'expression de tau
MA71468A MA71468A (fr) 2015-12-21 2016-12-19 Compositions et méthodes pour diminuer l'expression de tau

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA44426A MA44426B1 (fr) 2015-12-21 2016-12-19 Compositions et méthodes pour diminier l'expression de tau

Country Status (40)

Country Link
US (2) US11473083B2 (fr)
EP (3) EP4678748A2 (fr)
JP (4) JP7027328B2 (fr)
KR (2) KR20250112919A (fr)
CN (2) CN116218848A (fr)
AR (1) AR107579A1 (fr)
AU (2) AU2016376034B2 (fr)
CA (1) CA3008094A1 (fr)
CL (3) CL2018001652A1 (fr)
CO (1) CO2018006297A2 (fr)
CR (1) CR20200609A (fr)
CU (1) CU24574B1 (fr)
DK (1) DK3394259T3 (fr)
DO (1) DOP2018000151A (fr)
EA (2) EA036417B1 (fr)
EC (1) ECSP18050575A (fr)
ES (1) ES2984631T3 (fr)
FI (1) FI3394259T3 (fr)
HR (1) HRP20240672T1 (fr)
HU (1) HUE066548T2 (fr)
IL (3) IL305866B2 (fr)
JO (2) JO3790B1 (fr)
LT (1) LT3394259T (fr)
MA (2) MA44426B1 (fr)
MX (2) MX2018007726A (fr)
MY (1) MY191737A (fr)
PE (2) PE20181448A1 (fr)
PH (1) PH12018501207B1 (fr)
PL (1) PL3394259T3 (fr)
PT (1) PT3394259T (fr)
RS (1) RS65535B1 (fr)
RU (1) RU2747734C2 (fr)
SA (1) SA518391831B1 (fr)
SG (2) SG10201913434PA (fr)
SI (1) SI3394259T1 (fr)
SV (1) SV2018005714A (fr)
TW (2) TWI787163B (fr)
UY (1) UY37038A (fr)
WO (1) WO2017109679A1 (fr)
ZA (1) ZA201803661B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148283A1 (fr) 2012-03-30 2013-10-03 Isis Pharmaceuticals, Inc. Compositions et procédés pour moduler l'expression de tau pour réduire les crises d'épilepsie et modifier un syndrome neurodégénératif
TWI657819B (zh) 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
ES2963428T3 (es) 2016-09-29 2024-03-27 Biogen Ma Inc Compuestos y métodos para reducir la expresión de Tau
BR112020018365A2 (pt) 2018-03-13 2020-12-29 Janssen Pharmaceutica Nv Oligonucleotídeos modificados e métodos para uso em tauopatias
WO2020007892A1 (fr) 2018-07-03 2020-01-09 F. Hoffmann-La Roche Ag Oligonucléotides pour moduler l'expression de tau
MX2022012293A (es) * 2020-03-30 2022-10-27 Alnylam Pharmaceuticals Inc Composiciones de agentes de acido ribonucleico de interferencia (arni) de la proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
CN113817728A (zh) * 2020-06-19 2021-12-21 四川大学华西医院 一种有效干扰Tau蛋白表达的重组慢病毒及其应用
EP4355878A4 (fr) * 2021-06-16 2025-04-09 Empirico Inc. Traitement de maladies et de troubles liés à mtres1
EP4370680A4 (fr) * 2021-07-16 2025-08-13 Aptah Bio Inc Compositions polynucléotidiques et procédés de régulation de l'expression génique
MX2024003519A (es) 2021-09-24 2024-04-01 Alnylam Pharmaceuticals Inc Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
JP2025501682A (ja) * 2021-12-03 2025-01-23 クラリス コーポレーション 改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド
EP4608981A1 (fr) * 2022-10-25 2025-09-03 Empirico Inc. Traitement par thérapie génique de maladies et de troubles associés à mtres1
CN120958129A (zh) * 2023-01-18 2025-11-14 阿普塔生物公司 用于治疗癌症的多核苷酸组合物和方法
CN121127586A (zh) * 2023-01-18 2025-12-12 阿普塔生物公司 用于治疗神经退行性疾病的多核苷酸组合物和方法
CN121285630A (zh) * 2023-04-20 2026-01-06 阿达尔克斯制药有限公司 Mapt调节组合物及其使用方法
WO2025188990A1 (fr) * 2024-03-08 2025-09-12 Eli Lilly And Company Oligonucléotide antisens mapt
WO2025212467A1 (fr) * 2024-03-31 2025-10-09 Arrowhead Pharmaceuticals, Inc. Agents arni pour inhibition de l'expression de la protéine tau associée aux microtubules (mapt), compositions associées et procédés d'utilisation
WO2026025082A1 (fr) * 2024-07-25 2026-01-29 Biogen Ma Inc. Méthodes de traitement de la maladie d'alzheimer

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
HUT63170A (en) 1990-01-11 1993-07-28 Isis Pharmaceuticals Inc Process and composition for detecting and modifying rna activity and gene expression
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US20020052331A1 (en) 1990-08-14 2002-05-02 Brenda Baker Compositions and methods for antisense inhibition of protein translation
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
WO1993011231A1 (fr) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Outils de diagnostic et de traitement de la maladie d'alzheimer
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
AU680449B2 (en) * 1992-10-05 1997-07-31 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
KR940021073A (ko) 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
CA2116460A1 (fr) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Agents prophylactiques ou therapeutiques pour la maladie d'alzheimer, methode de depistage de la maladie d'alzheimer et tau-proteine kinase i extraite d'un organisme humain
EP1897942A1 (fr) 1993-05-11 2008-03-12 The University Of North Carolina At Chapel Hill Oligonucléotides anti-sens combattant l'épissage aberrant et leurs procédés d'utilisation
KR19990082476A (ko) 1996-02-14 1999-11-25 하우스 한스 루돌프, 긴터 베아트리체 당-변형되어 갭이 형성된 올리고뉴클레오티드
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
CA2303299C (fr) 1997-09-12 2016-02-23 Exiqon A/S Analogues d'oligonucleotides
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
EP1077990A1 (fr) 1998-05-01 2001-02-28 Mayo Foundation For Medical Education And Research Mutations tau pathogenes
US6664443B1 (en) 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
JP2002520054A (ja) * 1998-07-14 2002-07-09 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
PT1152009E (pt) 1999-02-12 2005-03-31 Sankyo Co Novos analogos de nucleosidos e oligonucleotidos
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
AU4471700A (en) 1999-04-26 2000-11-10 University Of North Carolina At Chapel Hill, The Antisense human fucosyltransferase sequences and methods of use thereof
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
CN101284873A (zh) * 1999-06-30 2008-10-15 科里克萨有限公司 用于肺癌治疗和诊断的组合物和方法
JP4151751B2 (ja) 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
WO2001053340A2 (fr) 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Modele murin transgenique de maladies neurodegeneratives humaines
CA2400595A1 (fr) * 2000-02-28 2001-09-07 Decode Genetics Ehf Gene humain de la schizophrenie
WO2002055681A2 (fr) 2001-01-11 2002-07-18 Bayer Ag Regulation de la tau-tubuline kinase humaine
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
AU2003247521A1 (en) 2002-06-26 2004-01-19 Isis Pharmaceuticals, Inc. Antisense inhibition via rnase h-independent reduction in mrna
US20050130924A1 (en) 2002-06-26 2005-06-16 Monia Brett P. Antisense inhibition via RNAse H-independent reduction in mRNA
US20080176812A1 (en) 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
ES2352668T3 (es) 2002-08-14 2011-02-22 Mitsubishi Chemical Medience Corporation Anticuerpo específico para una proteína tau del sistema nervioso central.
WO2004041889A2 (fr) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Composes oligomeres renfermant un substitut de sucre polycyclique et compositions intervenant dans la modulation genique
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7906326B2 (en) 2003-05-07 2011-03-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof
US8163896B1 (en) 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20070077553A1 (en) 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US7696334B1 (en) 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
US20130130231A1 (en) 2002-11-26 2013-05-23 Isaac Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
CA2536333C (fr) 2003-08-28 2013-01-08 Jan Weiler Double helice d'arn d'interference possedant des extremites franches et des modifications en 3'
EP1683862B1 (fr) * 2003-09-25 2012-08-01 Chiba-Prefecture Microreseau d'evaluation de pronostic neuroblastome et procede d'evaluation de pronostic de neuroblastome
US20070106066A1 (en) 2003-10-28 2007-05-10 Alexander Cherkasky Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
WO2005111211A2 (fr) * 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micro-arn et utilisations de ceux-ci
PL1766010T3 (pl) 2004-06-28 2011-07-29 Univ Western Australia Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
US7312035B2 (en) 2004-09-03 2007-12-25 Affymetrix, Inc. Methods of genetic analysis of yeast
WO2006060753A2 (fr) 2004-12-03 2006-06-08 Rhode Island Hospital Diagnostic et traitement de la maladie d'alzheimer
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US20070048756A1 (en) 2005-04-18 2007-03-01 Affymetrix, Inc. Methods for whole genome association studies
WO2007028065A2 (fr) 2005-08-30 2007-03-08 Isis Pharmaceuticals, Inc. Composes oligomeriques chimeriques pour la modulation de l'epissage
WO2007047913A2 (fr) 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions et procédés pour la modulation de l'expression du gène lmna
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
US7901882B2 (en) 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
WO2008002620A2 (fr) 2006-06-27 2008-01-03 University Of Virginia Patent Foundation Modèle cellulaire pour pathologie de la maladie d'alzheimer
US20100021914A1 (en) 2006-11-23 2010-01-28 Querdenker Aps Oligonucleotides for modulating target rna activity
US20080249058A1 (en) 2007-04-05 2008-10-09 Erik Roberson Agents that reduce neuronal overexcitation
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP2268811A1 (fr) 2008-03-07 2011-01-05 Santaris Pharma A/S Compositions pharmaceutiques pour le traitement de maladies associées aux microarn
JP5773535B2 (ja) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
BR122023023194A2 (pt) 2009-11-12 2023-12-26 The University Of Western Australia Oligonucleotídeo antissentido, composição e respectivo uso
US20150018223A1 (en) 2010-01-28 2015-01-15 University Of Massachusetts Lowell Methods of diagnosing tau-associated neurodegenerative diseases
EP2550360B1 (fr) 2010-03-24 2017-08-30 Mirrx Therapeutics A/s Oligonucléotides antisens bivalents
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2643341A4 (fr) 2010-11-23 2014-08-27 Mirrx Therapeutics As Oligonucléotides pour la modulation de l'activité d'arn cibles
EP2655621B1 (fr) 2010-12-20 2018-05-23 The General Hospital Corporation Arn non codants associés à polycomb
WO2012149438A1 (fr) * 2011-04-28 2012-11-01 Life Technologies Corporation Procédés et compositions pour pcr multiplexe
WO2013013165A2 (fr) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Utilisation de composés d'acide nucléique bloqué (lna) pour l'inhibition thérapeutique de mir-21 dans le lupus érythémateux systémique
WO2013148283A1 (fr) * 2012-03-30 2013-10-03 Isis Pharmaceuticals, Inc. Compositions et procédés pour moduler l'expression de tau pour réduire les crises d'épilepsie et modifier un syndrome neurodégénératif
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
SG11201407017WA (en) 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
CN104936977B (zh) 2012-10-24 2019-10-08 开普敦大学 微管修饰化合物
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
JP2016502858A (ja) 2012-12-20 2016-02-01 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するための改善されたエキソンスキッピング組成物
EA202090946A3 (ru) 2013-03-14 2021-07-30 Сарепта Терапьютикс, Инк. Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
CN111254145A (zh) * 2013-03-14 2020-06-09 Ionis制药公司 用于调节tau表达的组合物和方法
HRP20190382T1 (hr) 2013-03-14 2019-04-19 Sarepta Therapeutics, Inc. Pripravci koji preskaču ekson za liječenje mišićne distrofije
WO2014201306A1 (fr) 2013-06-12 2014-12-18 Oncoimmunin, Inc. Administration systémique in vivo d'oligonucléotides
TWI657819B (zh) * 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
WO2015068075A2 (fr) 2013-10-24 2015-05-14 Institut National De La Sante Et De La Recherche Medicale Détection de protéine tau
CN104711324A (zh) * 2013-12-11 2015-06-17 芮屈生物技术（上海）有限公司 老年性痴呆病变前期TAU基因的mRNA水平原位杂交筛查试剂盒
EP3736334A1 (fr) * 2014-07-16 2020-11-11 Arrowhead Pharmaceuticals, Inc. Compositions d'arni pour le traitement de pathologies liées à l'apoc3
WO2016019063A1 (fr) 2014-07-29 2016-02-04 Isis Pharmaceuticals, Inc. Compositions et méthodes pour moduler l'expression de tau
EP3253871A1 (fr) 2015-02-04 2017-12-13 Bristol-Myers Squibb Company Oligonucléotides lna à flancs alternés
EP3254104B1 (fr) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Procédés de sélection de molécules thérapeutiques
SG11201706293XA (en) 2015-02-04 2017-09-28 Hoffmann La Roche Tau antisense oligomers and uses thereof
US20170035860A1 (en) * 2015-04-02 2017-02-09 Alexander C. Flynn Compositions and methods for treatment of neurogenerative diseases

Also Published As

Publication number Publication date
BR112018012304A2 (pt) 2019-02-05
CL2019003420A1 (es) 2020-05-15
MX2018007726A (es) 2018-08-15
PT3394259T (pt) 2024-05-20
CL2019000149A1 (es) 2019-06-07
PL3394259T3 (pl) 2024-07-22
RU2747734C2 (ru) 2021-05-13
DOP2018000151A (es) 2018-09-15
EP4678748A2 (fr) 2026-01-14
EP4406541A3 (fr) 2024-10-16
CU20180065A7 (es) 2018-11-06
CU24574B1 (es) 2022-01-13
DK3394259T3 (da) 2024-05-27
UY37038A (es) 2017-07-31
SG11201804704PA (en) 2018-07-30
LT3394259T (lt) 2024-06-10
JP7594557B2 (ja) 2024-12-04
PH12018501207B1 (en) 2024-02-23
RU2018126545A (ru) 2020-01-23
HK1254822A1 (en) 2019-07-26
IL260124A (en) 2018-07-31
ECSP18050575A (es) 2018-07-31
ES2984631T3 (es) 2024-10-30
IL296844B1 (en) 2023-12-01
CO2018006297A2 (es) 2018-07-10
SV2018005714A (es) 2018-09-10
RU2018126545A3 (fr) 2020-10-12
WO2017109679A1 (fr) 2017-06-29
AU2020267282B2 (en) 2023-05-18
EP4406541A2 (fr) 2024-07-31
KR102834468B1 (ko) 2025-07-15
EA202091865A1 (ru) 2021-01-29
TW202311530A (zh) 2023-03-16
HRP20240672T1 (hr) 2024-08-16
NZ783034A (en) 2025-07-25
TWI787163B (zh) 2022-12-21
KR20180089517A (ko) 2018-08-08
SI3394259T1 (sl) 2024-07-31
EA201891468A1 (ru) 2018-12-28
CA3008094A1 (fr) 2017-06-29
JP2025026976A (ja) 2025-02-26
ZA201803661B (en) 2024-08-28
AU2016376034A1 (en) 2018-07-05
MY191737A (en) 2022-07-13
KR20250112919A (ko) 2025-07-24
FI3394259T3 (fi) 2024-05-24
PE20241069A1 (es) 2024-05-13
MX2023008211A (es) 2023-07-18
IL305866B1 (en) 2024-08-01
PE20181448A1 (es) 2018-09-12
EP3394259A1 (fr) 2018-10-31
JP2019500428A (ja) 2019-01-10
IL296844B2 (en) 2024-04-01
IL296844A (en) 2022-11-01
CL2018001652A1 (es) 2018-08-10
EP3394259B1 (fr) 2024-02-28
JP7027328B2 (ja) 2022-03-01
SG10201913434PA (en) 2020-03-30
IL305866A (en) 2023-11-01
JO3790B1 (ar) 2021-01-31
US11473083B2 (en) 2022-10-18
PH12018501207A1 (en) 2019-02-11
RU2021112980A3 (fr) 2021-12-28
CN109072237B (zh) 2022-12-16
IL305866B2 (en) 2024-12-01
AU2016376034B2 (en) 2020-12-03
RU2021112980A (ru) 2021-05-28
SA518391831B1 (ar) 2022-08-16
US20170175116A1 (en) 2017-06-22
JP2022065096A (ja) 2022-04-26
HUE066548T2 (hu) 2024-08-28
AU2020267282A1 (en) 2020-12-10
CN116218848A (zh) 2023-06-06
CR20200609A (es) 2021-02-17
RS65535B1 (sr) 2024-06-28
TW201733597A (zh) 2017-10-01
JOP20200228A1 (ar) 2020-09-13
US20220411796A1 (en) 2022-12-29
MA44426B1 (fr) 2024-05-31
NZ743231A (en) 2025-07-25
EA036417B1 (ru) 2020-11-09
CN109072237A (zh) 2018-12-21
TWI834177B (zh) 2024-03-01
JP2021118732A (ja) 2021-08-12
AR107579A1 (es) 2018-05-16

Similar Documents

Publication Publication Date Title
EP3679141C0 (fr) Méthodes et compositions pour inhiber l'expression de la ldha
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
EP3510152A4 (fr) Méthodes et compositions pour moduler l'expression génique
EP3523437A4 (fr) Compositions d'oligonucléotides et méthodes associées
EP3328377A4 (fr) Compositions et méthodes pour thérapies immuno-oncologiques
EP3532613A4 (fr) Méthodes et compositions pour le mappage d'arn
EP3356529A4 (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
EP3324978A4 (fr) Compositions d'oligonucléotides et méthodes associées
EP3353328A4 (fr) Modulateurs de l'expression de kras
EP3355954A4 (fr) Méthodes et compositions d'administration
EP3328363A4 (fr) Compositions et méthodes d'immunomodulation
EP3420083A4 (fr) Méthodes et compositions pour détection de cibles
EP3519572A4 (fr) Composés et procédés pour réduire l'expression de tau
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3472317A4 (fr) Compositions et méthodes destinées à réduire la néovascularisation oculaire
EP3436083A4 (fr) Nouvelles compositions et méthodes
IL260124A (en) Compounds and methods for reducing tau expression
EP3302588A4 (fr) Compositions et méthodes pour l'adhérence à des surfaces
EP3258925A4 (fr) Méthodes et compositions pour réduire la vidange gastrique
EP3352800A4 (fr) Méthodes et compositions pour réduire les métastases
EP3380095A4 (fr) Compositions et méthodes de traitement d'un avc ischémique
MA43378A (fr) Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
EP3380471A4 (fr) Méthodes et compositions d'inhibition de comt
EP3397288A4 (fr) Méthodes pour diminuer l'expression de l'ataxine-2
EP3302503A4 (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de hif2alpha